TADS
Testosterone-Guided Schedule of Androgen Deprivation Therapy (ADT) as an Alternative to A Fixed Schedule In Management Of Prostate Cancer
Sponsor study identifier
observational
82
1 country
1
Study Start
November 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2014
Actual (reported)Study Completion
June 2014
Actual (reported)The male sex-hormone called testosterone is known to play a key role in the growth of prostate cancer. The usual treatment for the disease involves suppression of hormones (testosterone) by anti-hormonal treatment for an unknown period of time until the cancer progresses. This anti-hormonal treatment usually consists of injections every three months with an LHRH(Leutinizing Hormone-Releasing Hormone) agonist and a short course of anti-androgen pills, which together help to lower the production of testosterone. Long-term hormonal treatment has potentially serious side effects and is expensive. In this study, hormonal treatments will be with held from those patients eligible and willing to participate. The aim of this study is to see if we can decrease the amount of hormone injections that patients require. This might lead to a decreased side effects(such as decrease in bone health, cardiovascular problems and metabolic syndrome which occurs when several health conditions happen at the same time and can lead to an increased risk of heart disease, stroke and diabetes) as well as to decrease the cost of hormonal therapy to treat prostate cancer.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2014
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 2009
Date type not reportedThis date has not been verified as actual or estimated.
January 22, 2010
Actual (reported)January 26, 2010
Actual (reported)June 2014
Actual (reported)June 2014
Actual (reported)We will monitor serum testosterone initially q 6 weeks increasing to every three months and delay initiating the next dose of ADT until serum testosterone level rises above 1.5nMol/l.
Baseline, Q6wks x 24 wks
Jamar Dynamometer
Baseline and 18 weeks
EPIC Quality of Life Questionnaire
Baseline and 18 weeks
Six Minute Walk Test
Baseline and 18 weeks
Men with prostate cancer attending ambulatory clinics at Princess Margaret Hospital
Princess Margaret Hospital
Toronto, Ontario, M5G2M9, Canada
Ian F Tannock, MD, PhD
University Health Network, Toronto
82 participants (actual enrollment reported by the registry).
First Submitted
January 22, 2010
First Posted
January 26, 2010
Study Start
November 2009
Date type not reportedThis date has not been verified as actual or estimated.
Fiducial Localization and Individualized Radiotherapy -Prostate Cancer
Contact the study team to confirm eligibility.
Primary Completion
June 2014
Actual (reported)Study Completion
June 2014
Actual (reported)Last Updated
April 27, 2015
Record last verified: 2015-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: